Atezolizumab: tested in a combination

244 studies: another drug in the study is under test too. Page 2 of 3. Open to participants first (57), then studies with results posted, then the rest; newest registration first within each.

• A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple MyelomaCompletedNCT03312530Phase 1/2Results postedReport a problem
• A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type MelanomaTerminatedNCT03273153Phase 3Results postedReport a problem
• Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial CancerTerminatedNCT03272217Phase 2Results postedReport a problem
• A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid TumorsCompletedNCT03264066Phase 2Results postedReport a problem
• Study of Talimogene Laherparepvec With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver MetastasesCompletedNCT03256344Phase 1Results postedReport a problem
• Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant MesotheliomaActive, not recruitingNCT03228537Phase 1Results postedReport a problem
• Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast CancerCompletedNCT03206203Phase 2Results postedReport a problem
• Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder CancerCompletedNCT03201458Phase 2Results postedReport a problem
• Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced MelanomaCompletedNCT03178851Phase 1Results postedReport a problem
• Atezolizumab in Combination With Temozolomide and Radiation Therapy in Treating Patients With Newly Diagnosed GlioblastomaCompletedNCT03174197Phase 1/2Results postedReport a problem
• Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare TumorsCompletedNCT03108131Phase 2Results postedReport a problem
• Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical CancerCompletedNCT02921269Phase 2Results postedReport a problem
• Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerActive, not recruitingNCT02839707Phase 2/3Results postedReport a problem
• Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial CarcinomaCompletedNCT02807636Phase 3Results postedReport a problem
• A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370)CompletedNCT02788279Phase 3Results postedReport a problem
• Study of Atezolizumab + Bevacizumab in Patients With Advanced Non-Clear Cell Renal Cell CarcinomaCompletedNCT02724878Phase 2Results postedReport a problem
• A Study of Atezolizumab in Combination With Bevacizumab Versus Sunitinib in Participants With Untreated Advanced Renal Cell Carcinoma (RCC)CompletedNCT02420821Phase 3Results postedReport a problem
• A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]CompletedNCT02367794Phase 3Results postedReport a problem
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02367781Phase 3Results postedReport a problem
• A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02366143Phase 3Results postedReport a problem
• A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has SpreadTerminatedNCT02322814Phase 2Results postedReport a problem
• A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)CompletedNCT02291289Phase 2Results postedReport a problem
• My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid TumorsCompletedNCT02091141Phase 2Results postedReport a problem
• A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PD-L1] Antibody) as Monotherapy or in Combination With Bevacizumab (Avastin®) Compared to Sunitinib (Sutent®) in Participants With Untreated Advanced Renal Cell CarcinomaCompletedNCT01984242Phase 2Results postedReport a problem
• The Effectiveness and Safety in High-risk Patients Receiving First-line Atezolizumab and Bevacizumab Combined With HAIC for HCC: a Retrospective StudyCompletedNCT07272265Not applicableReport a problem
• Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCATerminatedNCT06739252Phase 2Report a problem
• Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerSuspendedNCT06616623Phase 1Report a problem
• Perioperative Immunotherapy for NSCLC (ECTOP-1030)WithdrawnNCT06572722Phase 2Report a problem
• EF-39 PANOVA-4: Study of Tumor Treating Fields Concomitant With Atezolizumab, Gemcitabine and Nab-Paclitaxel as First-LineTreatment for Metastatic Pancreatic Ductal AdenocarcinomaCompletedNCT06390059Phase 2Report a problem
• A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors with Resectable Disease with Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H)WithdrawnNCT06331598Phase 2Report a problem
• Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent GlioblastomaWithdrawnNCT06328036Phase 2Report a problem
• Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal CancerActive, not recruitingNCT05999812Phase 2Report a problem
• Atezolizumab Immunotherapy With or Without Tiragolumab for Patients With Unresectable Stage III NSCLCActive, not recruitingNCT05798663Phase 2Report a problem
• Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung AdenocarcinomaActive, not recruitingNCT05689671Phase 4Report a problem
• Testing Anti-Cancer Drugs Erdafitinib With or Without Atezolizumab in Patients With Localized Bladder Cancer Not Able to Receive Cisplatin Chemotherapy, NERA TrialWithdrawnNCT05564416Phase 2Report a problem
• Evaluating Novel Therapies in ctDNA Positive GI CancersActive, not recruitingNCT05482516Phase 3Report a problem
• Neoadjuvant PD-1 Plus TIGIT Blockade in Patients With Cisplatin-Ineligible Operable High-Risk Urothelial CarcinomaActive, not recruitingNCT05394337Phase 1/2Report a problem
• Multinational Phase II Trial to Compare Safety and Efficacy of SIRT (Y-90 Resin Microspheres) Followed by Atezolizumab Plus Bevacizumab, vs SIRT (SIRT-Y90) Followed by Placebo in Locally Advanced HCC PatientsActive, not recruitingNCT05377034Phase 2Report a problem
• Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular CarcinomaWithdrawnNCT05327738Phase 2Report a problem
• PD-L1 Inhibitor Rechallenge After PD-1 Immunotherapy for Patients With Solid Tumor Beyond Lung CancerStatus unknownNCT05325684Phase 1/2Report a problem
• Thiopurine Enhanced Mutations for PD-1/Ligand-1 EfficacyCompletedNCT05276284Phase 1/2Report a problem
• Atezolizumab Plus CArboplatin Plus Nab-paclitaxelActive, not recruitingNCT05266937Phase 2Report a problem
• SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1Report a problem
• Impact of Neoadjuvant Immunotherapy in Early Stage Breast Cancer Before Standard TherapyTerminatedNCT05180006Phase 2Report a problem
• Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT05168618Phase 2Report a problem
• Neoadjuvant Combination of Atezolizumab/Bevacizumab Versus Neoadjuvant Radiation TherapyTerminatedNCT05137899Phase 2Report a problem
• An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)Active, not recruitingNCT05112965Phase 3Report a problem
• Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck CancersActive, not recruitingNCT05063552Phase 2/3Report a problem
• Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract CancerCompletedNCT05052099Phase 1/2Report a problem
• Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05039281Phase 1/2Report a problem
• Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT05007613Phase 2Report a problem
• Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLCCompletedNCT04997382Phase 2Report a problem
• Frontline Treatment of Follicular Lymphoma With AtezolizUmab and Obinutuzumab With and Without RadiOtherapyActive, not recruitingNCT04962126Phase 2Report a problem
• A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian TumorsActive, not recruitingNCT04931342Phase 2Report a problem
• All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung CancerCompletedNCT04919369Phase 1Report a problem
• SBRT + Atezolizumab + Bevacizumab in Resectable HCCActive, not recruitingNCT04857684Early Phase 1Report a problem
• Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyTerminatedNCT04801966Not applicableReport a problem
• Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)CompletedNCT04739202Phase 2Report a problem
• A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast CancerCompletedNCT04732598Phase 3Report a problem
• Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung CancerCompletedNCT04730999Phase 2Report a problem
• Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II TrialActive, not recruitingNCT04727307Phase 2Report a problem
• Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable MelanomaActive, not recruitingNCT04722575Phase 2Report a problem
• Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver CancerActive, not recruitingNCT04721132Phase 2Report a problem
• Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBCActive, not recruitingNCT04630730Phase 2Report a problem
• Investigating Atezolizumab in Newly Diagnosed ER Positive Breast Cancer Patients According to Their AdipOsityWithdrawnNCT04630210Early Phase 1Report a problem
• Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung CancerCompletedNCT04622228Phase 2Report a problem
• Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform StudyActive, not recruitingNCT04589845Phase 2Report a problem
• CRAFT: The NCT-PMO-1602 Phase II TrialCompletedNCT04551521Phase 2Report a problem
• A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Phase 3Report a problem
• Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian CancerWithdrawnNCT04510584Phase 2Report a problem
• Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung CancerCompletedNCT04487756Phase 1/2Report a problem
• SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph IICompletedNCT04480372Phase 2Report a problem
• First Line Atezolizumab, Paclitaxel, and Bevacizumab (Avastin®) in mTNBCCompletedNCT04408118Phase 2Report a problem
• A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic MelanomaActive, not recruitingNCT04356729Phase 2Report a problem
• A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)Active, not recruitingNCT04302025Phase 2Report a problem
• Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr CancerActive, not recruitingNCT04289779Phase 2Report a problem
• Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid TumorsTerminatedNCT04276376Phase 2Report a problem
• Abemaciclib With or Without Atezolizumab in Metastatic Castration Resistant Prostate CancerWithdrawnNCT04272645Phase 2Report a problem
• Cryoablation, Atezolizumab/Nab-paclitaxel for Locally Advanced or Metastatic Triple Negative Breast CancerWithdrawnNCT04249167Early Phase 1Report a problem
• MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue SarcomaCompletedNCT04216953Phase 1/2Report a problem
• A MolEcularly Guided Anti-Cancer Drug Off-Label TrialActive, not recruitingNCT04185831Phase 2Report a problem
• Atezolizumab Plus Bevacizumab With HCC and HBV InfectionActive, not recruitingNCT04180072Not applicableReport a problem
• Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid TumorsCompletedNCT04157985Phase 3Report a problem
• A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors.CompletedNCT04147351Phase 2Report a problem
• Atezolizumab and BCG in High Risk BCG naïve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)Active, not recruitingNCT04134000Phase 1Report a problem
• ObinutuzuMab AtezOlizumab and VenetocLax in RichTer transfOrmationActive, not recruitingNCT04082897Phase 2Report a problem
• A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung CancerCompletedNCT04028050Phase 3Report a problem
• Neoadjuvant Treatment in Rectal Cancer With Radiotherapy Followed by Atezolizumab and Bevacizumab (TARZAN)Active, not recruitingNCT04017455Phase 2Report a problem
• Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLCStatus unknownNCT03991403Phase 3Report a problem
• TAHP for Patients With HER2-positive Early Breast Cancer and Subsequent AHP Adjuvant tHerapy After SurgeryStatus unknownNCT03881878Phase 1/2Report a problem
• Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and NeckCompletedNCT03818061Phase 2Report a problem
• Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast CancerCompletedNCT03802604Early Phase 1Report a problem
• Trial to Evaluate Safety and Efficacy of Vinorelbine With Metronomic Administration in Combination With Atezolizumab as Second-line Treatment for Patients With Stage IV Non-small Cell Lung CancerCompletedNCT03801304Phase 2Report a problem
• Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage IV NSCLCActive, not recruitingNCT03786692Phase 2Report a problem
• Phase I/II Study of Perioperative Chemotherapy Plus Immunotherapy Followed by Surgery in Localized Esophageal and Gastroesophageal AdenocarcinomaActive, not recruitingNCT03784326Phase 2Report a problem
• A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3Report a problem
• Efficacy and Safety of Atezolizumab Plus Capecitabine Adjuvant Therapy for Triple Receptor-Negative Breast CancerActive, not recruitingNCT03756298Phase 2Report a problem
• Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and NeckActive, not recruitingNCT03708224Phase 2Report a problem
• Treatment of Colorectal Liver Metastases With Immunotherapy and BevacizumabCompletedNCT03698461Phase 2Report a problem
• A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian CancerCompletedNCT03695380Phase 1Report a problem

← Atezolizumab